Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis.
Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis.
复制标题
靶向血小板中 Src SH3 的 RT 环可在不影响止血的情况下预防血栓形成
DOI：
10.1002/advs.202103228
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Xi X
中科院分区：
文献类型：
--
作者：
Mao J;Zhu K;Long Z;Zhang H;Xiao B;Xi W;Wang Y;Huang J;Liu J;Shi X;Jiang H;Lu T;Wen Y;Zhang N;Meng Q;Zhou H;Ruan Z;Wang J;Luo C;Xi X
Conventional antiplatelet agents indiscriminately inhibit both thrombosis and hemostasis, and the increased bleeding risk thus hampers their use at more aggressive dosages to achieve adequate effect. Blocking integrin αIIbβ3 outside‐in signaling by separating the β3/Src interaction, yet to be proven in vivo, may nonetheless resolve this dilemma. Identification of a specific druggable target for this strategy remains a fundamental challenge as Src SH3 is known to be responsible for binding to not only integrin β3 but also the proteins containing the PXXP motif. In vitro and in vivo mutational analyses show that the residues, especially E97, in the RT loop of Src SH3 are critical for interacting with β3. DCDBS84, a small molecule resulting from structure‐based virtual screening, is structurally validated to be directed toward the projected target. It specifically disrupts β3/Src interaction without affecting canonical PXXP binding and thus inhibits the outside‐in signaling‐regulated platelet functions. Treatment of mice with DCDBS84 causes a profound inhibition of thrombosis, equivalent to that induced by extremely high doses of αIIbβ3 antagonist, but does not compromise primary hemostasis. Specific targets are revealed for a preferential inhibition of thrombosis that may lead to new classes of potent antithrombotics without hemorrhagic side effects. Patients receiving aggressive treatment with conventional antiplatelet agents are subject to the risk of bleeding. DCDBS84, a small molecule specifically targeting c‐Src SH3 RT‐loop around E97, achieves a potent antithrombotic effect without compromising primary hemostasis by selectively blocking outside‐in signaling through integrin αIIbβ3. A new strategy for the development of antithrombotic therapies is provided here.
登录
查看更多内容
含 RGT 的肽靶向 c-Src 作为新型抗血栓策略的评估。
影响因子：
28.5
作者：
Huang J;Shi X;Xi W;Liu P;Long Z;Xi X
通讯作者：
Xi X
影响因子：
24
作者：
Amin AP;Wang TY;McCoy L;Bach RG;Effron MB;Peterson ED;Cohen DJ
通讯作者：
Cohen DJ
影响因子：
2.9
作者：
Lemmens, HJM;Bernstein, DP;Brodsky, JB
通讯作者：
Brodsky, JB
影响因子：
82.9
作者：
Falati, S;Gross, P;Furie, B
通讯作者：
Furie, B
影响因子：
56.9
作者：
FENG, SB;CHEN, JK;SCHREIBER, SL
通讯作者：
SCHREIBER, SL